Kythera deal

[hellouser]

PGE2 + PGD2 inhibition in tandem could work VERY well for hair loss.

[kantian]

I owned options and stock in Kythera. I think we got ripped off by Allergan. The company is worth more than that, and I'll vote against the acquisition when given the chance.

That being said, I do think this is promising for us hair loss sufferers. I don't think bim or seti will be out soon though, and they might be very highly priced even when they come to market.

[Ziggyz123]

Cornering the Hairloss market? Eh, I'm taking this whole acquisition with a grain of salt. I understand that allergan is the company with bimatoporost trials and what not, but they are the makers of Botox... Before kythera was developing this treatment, Botox was like the number one injectable for cosmetic purposes.. They obviously want to profit off of the double chin injectable because it is a similar product and an injectable. I understand the connection between bim with allergan and seti with kythera, but idk.. I am definitely not getting my hopes up not jumping to conclusions yet. To think that allergan has that much faith in a drug the "may" stop Hairloss and try and team it up with their own drug is reaching. Seems like they simply want to control and keep controlling the injectables market.

[It's2014ComeOnAlready]

I owned options and stock in Kythera. I think we got ripped off by Allergan. The company is worth more than that, and I'll vote against the acquisition when given the chance.

That being said, I do think this is promising for us hair loss sufferers. I don't think bim or seti will be out soon though, and they might be very highly priced even when they come to market.

Ripped off? The Wall Street Journal and Forbes both thought the acquisition was "pricey." Also regarding a release date for bim, if it was successful in phase 2b, it's very likely that we'd see it by this fall/winter. Setipiprant may be a few more years, however, if the 21st century cures act is signed into law, we could see it much sooner.

[Sogeking]

Cornering the Hairloss market? Eh, I'm taking this whole acquisition with a grain of salt. I understand that allergan is the company with bimatoporost trials and what not, but they are the makers of Botox... Before kythera was developing this treatment, Botox was like the number one injectable for cosmetic purposes.. They obviously want to profit off of the double chin injectable because it is a similar product and an injectable. I understand the connection between bim with allergan and seti with kythera, but idk.. I am definitely not getting my hopes up not jumping to conclusions yet. To think that allergan has that much faith in a drug the "may" stop Hairloss and try and team it up with their own drug is reaching. Seems like they simply want to control and keep controlling the injectables market.

Yes I'm with you on this. I do hope it will speed up the release of Seti. But on some acquisitions, development of some drugs were known to be buried. Time will tell I guess.

[It's2014ComeOnAlready]

Yes I'm with you on this. I do hope it will speed up the release of Seti. But on some acquisitions, development of some drugs were known to be buried. Time will tell I guess.

They mentioned in their conference call today, specifically stating how excited they are to develop setipiprant.

[Arieux]

Are there any officially anticipated dates when it comes to commercialisation of Setipiprant? It is in which trial phase actually?

[burtandernie]

Most important thing is just timelines that both things keep moving and get to the finish line. Mergers can throw things into limbo sometimes although it seems pretty unlikely here.

[Justinian]

Are there any officially anticipated dates when it comes to commercialisation of Setipiprant? It is in which trial phase actually?

Setipiprant has completed Phase 3 for asthma. I believe Kythera stated they would start in Phase 2 for hair loss.

Here is an interesting quote: "Combination Therapy: The true Holy Grail may come from combining a drug like Latisse with a certain type of medication commonly used to treat allergies and asthma. The medication blocks a hormone-like substance that prevents hair from growing. A treatment like this might help with hair growth. 'Using these drugs in combination is like taking your foot off-break and stepping on gas at the same time,' Washenik says. "

http://www.webmd.com/skin-problems-and-treatments/hair-loss/news/20140331/hair-loss-treatments-pipeline

The negotiations of this merger probably played a role in Allergan not releasing the Bimatoprost results yet. I wonder how they are going to proceed now. Phase 3 for bim and Phase 2 for setipiprant and get them both approved separately? A phase 2 with the combination compared against Bim by itself? Or maybe a Phase 3 combination somehow?

[HairlossAt15]

This is great news, in the conference call they said that they will speed up the double chin drug thing and file ind for setipiprant soon

[It's2014ComeOnAlready]

Just a thought - This deal with Kythera is mostly to do with Allergan wanting to dominate the aesthetics market of the entire head. This includes the injectables for the face, and with the move to acquire Seti, they will cover hair loss as well. In order to cover hair loss properly, they will need a drug that works very well to stop it (seti), as well as a drug that's effective in regrowing (bim).

This was a genius move. I hope we'll hear something about bimatoprost soon. It's understandable why they'd want both Kybella and Seti, but in most cases bim and seti will be co-dependent. Anyone who starts losing hair, or has hair thin out, and stops it with Seti, will want their full head of hair back. They get a prescription for seti, apply some bim, and it's over.

The CEO didn't speak much about seti, because it's his job to present the case to shareholders and investors why they made the move on the drug that's already been proven in clinical trials.

Another point - both are dependent on prostaglandin science. When phase 2b was over for bim, Kythera soon after announced trials for seti. Many people at Kythera used to work for Allergan, therefore it's very likely they were in communication. Allergan then buys Kythera, and plans to develop seti, even though it's the first "hypothesis-driven" approach to drug development AND many MPB drugs have failed up to this point. They know seti will work because of the results they've seen from bim, but also because of the work and science that Cotsarelis has presented.

One last exciting point - there is a bill that was passed unanimously (51-0) by the Energy and Commerce committee in a very bi-partisan fashion (rare these days). This bill is known as the "21st Century Cures Act." It plans to do, among other things, speed up the clinical trial process by modernizing and streamlining from the time of discovery through to the time it gets to market. It's soon going to be presented to congress, and should very likely be passed. If signed into law, it's likely that the clinical trial process for a drug like setipiprant will be accelerated.

[hellouser]

Just a thought - This deal with Kythera is mostly to do with Allergan wanting to dominate the aesthetics market of the entire head. This includes the injectables for the face, and with the move to acquire Seti, they will cover hair loss as well. In order to cover hair loss properly, they will need a drug that works very well to stop it (seti), as well as a drug that's effective in regrowing (bim).

This was a genius move. I hope we'll hear something about bimatoprost soon. It's understandable why they'd want both Kybella and Seti, but in most cases bim and seti will be co-dependent. Anyone who starts losing hair, or has hair thin out, and stops it with Seti, will want their full head of hair back. They get a prescription for seti, apply some bim, and it's over.

The CEO didn't speak much about seti, because it's his job to present the case to shareholders and investors why they made the move on the drug that's already been proven in clinical trials.

Another point - both are dependent on prostaglandin science. When phase 2b was over for bim, Kythera soon after announced trials for seti. Many people at Kythera used to work for Allergan, therefore it's very likely they were in communication. Allergan then buys Kythera, and plans to develop seti, even though it's the first "hypothesis-driven" approach to drug development AND many MPB drugs have failed up to this point. They know seti will work because of the results they've seen from bim, but also because of the work and science that Cotsarelis has presented.

One last exciting point - there is a bill that was passed unanimously (51-0) by the Energy and Commerce committee in a very bi-partisan fashion (rare these days). This bill is known as the "21st Century Cures Act." It plans to do, among other things, speed up the clinical trial process by modernizing and streamlining from the time of discovery through to the time it gets to market. It's soon going to be presented to congress, and should very likely be passed. If signed into law, it's likely that the clinical trial process for a drug like setipiprant will be accelerated.

Many of us, no wait.... damn near all of us don't or won't give a rats ass about accelerating setipirant as a hair loss treatment. Just release it already. The same goes for Follica and anything to do with stem cells.

[Ziggyz123]

Just a thought - This deal with Kythera is mostly to do with Allergan wanting to dominate the aesthetics market of the entire head. This includes the injectables for the face, and with the move to acquire Seti, they will cover hair loss as well. In order to cover hair loss properly, they will need a drug that works very well to stop it (seti), as well as a drug that's effective in regrowing (bim).

This was a genius move. I hope we'll hear something about bimatoprost soon. It's understandable why they'd want both Kybella and Seti, but in most cases bim and seti will be co-dependent. Anyone who starts losing hair, or has hair thin out, and stops it with Seti, will want their full head of hair back. They get a prescription for seti, apply some bim, and it's over.

The CEO didn't speak much about seti, because it's his job to present the case to shareholders and investors why they made the move on the drug that's already been proven in clinical trials.

Another point - both are dependent on prostaglandin science. When phase 2b was over for bim, Kythera soon after announced trials for seti. Many people at Kythera used to work for Allergan, therefore it's very likely they were in communication. Allergan then buys Kythera, and plans to develop seti, even though it's the first "hypothesis-driven" approach to drug development AND many MPB drugs have failed up to this point. They know seti will work because of the results they've seen from bim, but also because of the work and science that Cotsarelis has presented.

One last exciting point - there is a bill that was passed unanimously (51-0) by the Energy and Commerce committee in a very bi-partisan fashion (rare these days). This bill is known as the "21st Century Cures Act." It plans to do, among other things, speed up the clinical trial process by modernizing and streamlining from the time of discovery through to the time it gets to market. It's soon going to be presented to congress, and should very likely be passed. If signed into law, it's likely that the clinical trial process for a drug like setipiprant will be accelerated.

I like it when you talk dirty, it's2014comeonalready

J.k, but yeah I recently read about that bill being presented to congress. This is really great news. Thanks for that update man, much appreciated and well related.

[Ziggyz123]

I just wish that we knew how effective bim is from the trials. clearly that research that kythera did 2 years before announcing setipriprant was VERY promising.

[It's2014ComeOnAlready]

I'm not hopelessly optimistic, because I've been losing my hair for long enough (3 years). But, I gotta say, it really looks like things are falling into place.